OverviewSuggest Edit

Shin Nippon Biomedical Laboratories (SNBL Japan, 株式会社 新日本科学) is a contract research organization specializing in preclinical and clinical studies. It offers GLP (good laboratory practice), toxicity, pathology, pharmacokinetics, translational, and other research services. The company serves the pharmaceutical industry.

TypePublic
Founded1957
HQChuo City, JP
Websitesnbljapan.com

Latest Updates

Employees (est.) (Dec 2021)1,005(+3%)
Revenue (FY, 2020)$133.8 M(-5%)
Share Price (Nov 2021)¥1.8 K(+5%)
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at SNBL

Ryoichi Nagata

Ryoichi Nagata

Chairman, President & CEO
Hideshi Tsusaki

Hideshi Tsusaki

President, Preclinical Services
Satoshi Matsumoto

Satoshi Matsumoto

Exective Director
Show more

SNBL Office Locations

SNBL has offices in Chuo City, Kagoshima, Kobe, Minato City and in 4 other locations
Chuo City, JP (HQ)
St Luke's Tower 28F, 8-1 Akashi-cho, Chuo-ku, Tokyo,104-0044, Japan
Kobe, JP
1-chōme-6-5 Minatojima Minamimachi, Chūō-ku
Minato City, JP
Akasaka
Osaka, JP
1 Chome-1 Fushimimachi, Chuo Ward
Tsukuba, JP
2-chōme-1-6 Sengen
Everett, WA, US
6605 Merrill Creek Pkwy
Show all (8)

SNBL Financials and Metrics

SNBL Revenue

Embed Graph
View revenue for all periods
SNBL's revenue was reported to be $133.8 m in FY, 2020 which is a 5.2% decrease from the previous period.
USD

Revenue (H1, 2021)

66.2m

Gross profit (H1, 2021)

32.4m

Gross profit margin (H1, 2021), %

49%

Net income (H1, 2021)

10.8m

EBIT (H1, 2021)

11.0m

Market capitalization (10-Nov-2021)

67.3b

Closing stock price (10-Nov-2021)

1.8k

Cash (31-Dec-2020)

61.6m

EV

67.4b
SNBL's current market capitalization is ¥67.3 b.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

156.3m141.1m133.8m

Revenue growth, %

(10%)(5%)

Cost of goods sold

107.3m85.4m63.8m

Gross profit

49.0m55.7m70.0m
Half Year
USDH1, 2018H1, 2019H1, 2020H1, 2021

Revenue

67.0m78.2m59.2m66.2m

Cost of goods sold

47.4m52.1m26.8m33.8m

Gross profit

19.6m26.1m32.4m32.4m

Gross profit Margin, %

29%33%55%49%
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

50.0m46.3m48.2m

Accounts Receivable

24.1m17.9m23.9m

Inventories

60.6m32.4m37.0m

Current Assets

143.9m105.1m114.0m
Quarterly
Annual
USDFY, 2018FY, 2019FY, 2020

Depreciation and Amortization

13.9m12.3m11.3m

Inventories

3.7m(3.8m)(4.1m)

Accounts Payable

(21.9k)1.1m759.8k

Cash From Operating Activities

12.7m26.1m27.7m
Half Year
USDH1, 2018H1, 2019H1, 2020H1, 2021

Depreciation and Amortization

6.7m6.9m5.2m5.4m

Inventories

(2.1m)(4.8m)(6.0m)(351.3k)

Accounts Payable

489.7k1.7m366.0k(244.8k)

Cash From Operating Activities

(3.2m)10.9m12.3m9.6m
Show all financial metrics

SNBL Operating Metrics

Nov, 2020

Awards

2

Patents (US)

26

Trademarks (US)

5

Types of Services

4
Show all operating metrics

SNBL Acquisitions / Subsidiaries

Company NameDateDeal Size
Gemseki Inc

SNBL Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

SNBL Online and Social Media Presence

Embed Graph

SNBL News and Updates

SNBL to participate in development of a prophylactic DNA vaccine for COVID-19

SNBL has announced their intention to participate in the development of a prophylactic DNA vaccine for SARS-CoV-2, the disease which causes COVID-19.

Japan's State of Emergency and SNBL

On April 7, 2020, Japanese Prime Minister Shinzo Abe declared a state of emergency in 7 areas of Japan due to COVID-19, including large cities such as Tokyo and Osaka. This does not apply to the areas in which SNBL's two major laboratories are located.

SNBL Client CytoDyn Files IND for Respiratory Complications Therapy due to COVID-19

A client of Shin Nippon Biomedical Laboratories, Ltd. (hereafter, SNBL), CytoDyn Inc. (Vancouver, Washington, USA, hereafter CytoDyn) has filed an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) in order to conduct a Phase 2 clinical trial using leronlimab (…

SNBL to be represented by Medgaea Life Sciences, Ltd. in Taiwan

SNBL and Medgaea Life Sciences, Ltd. (MDG) have signed an agreement for Medgaea Life Sciences to represent SNBL in Taiwan.

SNBL Blogs

Consolidated Financial Results for the Six Months of the Fiscal Year Ending March 31, 2022

Consolidated Financial Results for the Six Months of the Fiscal Year Ending March 31, 2022 Financial Results 1H FY202203.pdf Adobe Acro…

Revisions of the Earnings Forecasts for the Six Months and Full-Year of the FY Ending March 31, 2022

SNBL revised its earnings forecasts for the six months and full-year of the fiscal year ending March 31, 2022. Revisions of the Earnings Forecasts 1H & Full-Year FY2022/3 …

Notice Regarding Establishment of SDGs Committee

SNBL has established a Sustainable Developmental Goals (SDGs) committee. Please see the link below for more details. Notice Regarding Establishment of SDGs Committee …

SNBL Frequently Asked Questions

  • When was SNBL founded?

    SNBL was founded in 1957.

  • Who are SNBL key executives?

    SNBL's key executives are Ryoichi Nagata, Hideshi Tsusaki and Satoshi Matsumoto.

  • How many employees does SNBL have?

    SNBL has 1,005 employees.

  • What is SNBL revenue?

    Latest SNBL annual revenue is $133.8 m.

  • What is SNBL revenue per employee?

    Latest SNBL revenue per employee is $133.1 k.

  • Who are SNBL competitors?

    Competitors of SNBL include Covance, Charles River Laboratories and Envigo.

  • Where is SNBL headquarters?

    SNBL headquarters is located at St Luke's Tower 28F, 8-1 Akashi-cho, Chuo-ku, Tokyo,104-0044, Japan, Chuo City.

  • Where are SNBL offices?

    SNBL has offices in Chuo City, Kagoshima, Kobe, Minato City and in 4 other locations.

  • How many offices does SNBL have?

    SNBL has 8 offices.